Abolaji Atomode
Impact in
- Virology top 10%
- Poxvirus research and outbreaks
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 6
-
- Antibiotic Use and Resistance 1
Abolaji Atomode
9 papers receiving 446 citations
Abolaji Atomode's Hit Papers
Peers
Comparison fields: 5 of 54
- Virology 75
- Infectious Diseases 222
- Applied Microbiology and Biotechnology 3
- Epidemiology 31
- Pulmonary and Respiratory Medicine 29
Countries citing papers authored by Abolaji Atomode
This map shows the geographic impact of Abolaji Atomode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abolaji Atomode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abolaji Atomode more than expected).
Fields of papers citing papers by Abolaji Atomode
This network shows the impact of papers produced by Abolaji Atomode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abolaji Atomode. The network helps show where Abolaji Atomode may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 2 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 3 | 2022 | 81 | |
| 4 | 2023 | 25 | |
| 5 | 2024 | 24 | |
| 6 | 2023 | 6 | |
| 7 | 2024 | 6 | |
| 8 | 2025 | 5 | |
| 9 | 2025 | 2 |
About Abolaji Atomode
Abolaji Atomode is a scholar working on Infectious Diseases, Applied Microbiology and Biotechnology, Virology, Surgery and Nuclear Energy and Engineering, having authored 9 papers that have together received 464 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Antibiotic Use and Resistance (1 paper), Poxvirus research and outbreaks (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Virology (75 citations), Infectious Diseases (222 citations), Applied Microbiology and Biotechnology (3 citations), Epidemiology (31 citations) and Pulmonary and Respiratory Medicine (29 citations). Abolaji Atomode has collaborated with scholars based in United Kingdom. Their work appears in journals such as The Lancet, The Lancet Infectious Diseases, EClinicalMedicine, Nature Communications and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.